VANCOUVER, British Columbia and MENLO PARK, Calif., May, 17, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (`DelMar` or the `Company`), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the third quarter ended March 31, 2018. DelMar executive management will host a business update conference call for investors, analysts and other interested parties on May 30, 2018 at 4:30 p.m. Eastern Time. `This quarter has been a pivotal and important period for DelMar. I am pleased with our enhanced focus on leveraging VAL-083`s unique mechanism of action to advance both of our Phase 2 clinical programs including...
|
